Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Clinical trial NCT03939026 · COMPLETED
Trial details
- NCT number
- NCT03939026
- Sponsor
- Allogene Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-01
- Primary completion
- 2021-10-23
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.